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Abstract
Objectives A centralised approach to health technology assessment (HTA) may facilitate optimal use of HTA resources. 
A regional approach may increase the chances of local implementation of recommendations. This study aimed to compare 
assessment procedures in England (centralised HTA approach) with Spain (regional HTA approach) discussing key chal-
lenges and opportunities from both approaches.
Methods We compared technology assessments of anticancer medicines in the two jurisdictions from 2008 to 2015. To 
assess the implementation of HTA recommendations, we assessed trends in medicine usage using regression methods. We 
used IQVIA data, from 2011 to 2016, for a sample of 11 medicines. We used CatSalut data from Catalonia to assess the 
implementation of local recommendations.
Results In England, 66 assessments were undertaken by the National Institute for Health and Care Excellence (NICE), using 
a standardised methodology. In Spain, there were 79 reports undertaken by a range of bodies using a shared process and 
coordinated through the GENESIS collaboration; the assessment methods used varied substantially. Overall, the recom-
mendations in the two jurisdictions were similar. Regression analyses indicate that where there is a positive recommendation 
by HTA bodies, the usage of the medicine responds most strongly (p < 0.001) in Catalonia (4.892), followed by England 
(3.120) and Spain (1.693).
Conclusions This study suggests that medicine utilisation does respond to the positive recommendations of HTA bodies. 
However, if HTA capacity is organised primarily regionally, considerable effort may be required in coordination, to ensure 
consistent and rigorous assessments and adequate implementation of HTA findings.
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Introduction
Different jurisdictions organise their health technology 
assessment (HTA) capacity in different ways. Some estab-
lish capacity at the central level and undertake assessments 
that result in recommendations for the whole country; others 
establish capacity at the regional level resulting in several 
HTA bodies within the same country and the possibility of 
several, potentially different sets of recommendations. In 
principle, a centralised approach offers the potential to pool 
the scarce resources devoted to HTA, to conduct consist-
ent assessments and issue national recommendations that 
may encourage a uniform development of services across 
the whole country.
At the European level, this rationale of “economies of 
scale” is also being supported by the recent European Com-
mission proposal for Regulation on HTA (European Com-
mission. Regulation of the European Parliament and of the 
Council on health technology assessment and amending 
Directive 2011/24/EU. https ://ec.europ a.eu/healt h/sites /
healt h/files /techn ology _asses sment /docs/com20 18_51fin 
al_en.pdf (2018). (Accessed 29 Mar 2019), although strictly 
speaking, the proposal is only about joint clinical assess-
ments, leaving economic evaluation as a member state 
competency. On the other hand, a regional approach may be 
more fragmented, but may help in tailoring recommenda-
tions to local needs, perhaps encouraging a greater adoption 
of the recommendations made.
England is an example of a country following primarily 
a centralised approach. Assessments of medicines and other 
health technologies are conducted by the National Institute 
for Health and Care Excellence (NICE), which follows a 
consistent methodology [1, 2]. Based on a review of the 
clinical and economic evidence, the incremental cost per 
quality-adjusted life-year (QALY) of the new technology is 
estimated and compared with NICE’s ‘threshold’ of accept-
able incremental cost-effectiveness [3]. This threshold can 
be increased for end-of-life treatments if the criteria in the 
end-of life protocol are demonstrated [4], or for highly spe-
cialised technologies including medicines for ultra-rare dis-
eases [5]. Recommendations are then issued to the National 
Health Service (NHS) in England, which is obliged to fund 
those technologies that receive positive recommendations 
within 3 months.
An important feature of NICE recommendations in recent 
years is the application of Patient Access Schemes (PAS). 
Under this approach, the NICE recommendation (whether 
‘recommended ‘or ‘restricted’) is conditional on the manu-
facturer offering a PAS, which usually involves a confiden-
tial price discount.
Additionally, the Cancer Drugs Fund (CDF) has pro-
vided a complementary source of funding for those cancer 
medicines not having positive recommendations from NICE. 
It was established (as a temporary measure) by the Govern-
ment in 2011 to provide expanded patient access for cancer 
medications. However, after exceeding its allocated budget 
each year since 2014, a new framework for the CDF was 
established in 2016 [6], to become a “managed access fund”. 
The new approach allows NICE to recommend medicines 
for use within the CDF in situations where it considers that 
a highly promising medicine in an area of high unmet need 
area satisfies the criteria for routine use in the NHS, but still 
has remaining uncertainty about clinical and cost-effective-
ness. The final recommendation for the medicine is then 
issued after further evidence has been generated, generally 
after 2 years. The recent changes to the CDF have had a 
marked effect, increasing the overall approval rate of deci-
sions recommending routine use and managed access via 
the CDF [7].
By contrast, Spain is an example of a country following 
primarily a regional HTA approach, with 17 regions having 
complete control of their own health budget. Nevertheless, at 
the central level, once a medicine is licensed (by the Agencia 
Espa Española de Medicamentos y Productos Sanitatios), 
the Ministerio de Sanidad, Consumo y Bienestar Social 
(MSC) decides on its reimbursement and pricing based, 
among other things, on an assessment of therapeutic value, 
although there is lack of clarity in how these assessments are 
done, and their impact on the decision. Importantly, there is 
no HTA assessment similar to NICE’s. A positive recom-
mendation by the MSC implies that the medicine is approved 
for regional use and, although regions could reverse the cen-
tral decision, this rarely happens.
However, hospital budgets are limited, so their pharmaco-
therapeutic commissions, usually led by hospital pharma-
cists, often fund the medicine conditional on very specific 
clinical and cost criteria. The impact that economic evalua-
tion has had in informing national and local policies within 
the health care systems of England and Spain differs sub-
stantially [8, 9]. In Spain, although the MSC has commis-
sioned two proposals for methodological standardisation 
of economic analysis [10], there are currently no formal 
requirements for cost-effectiveness, although it is a criterion 
included in the legislation. Regardless of the methods that 
have been proposed by academic groups [11, 12], economic 
evaluation is not systematically used in health policy deci-
sion making in Spain.
This hierarchical approach in Spain has led to a com-
plex HTA system for pharmaceuticals that involves multiple 
organisations and potentially multiple assessments for the 
same medicine at three different levels [13]. At the national 
level, the MSC issues Informes de Posicionamiento (IPT) 
reports, but these concentrate mainly on effectiveness (it 
can be considered as a “clinical HTA”, and similar to the 
proposed EU joint clinical assessment mentioned above). 
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At the regional level, there are a number of bodies assess-
ing pharmaceuticals both in primary and secondary care. 
Since 2004, hospital pharmacy units within the country 
have been coordinated through the Grupo de Evaluación de 
Novedades, EStandarización e Investigación en Selección de 
Medicamentos (GENESIS) collaboration, led by the Spanish 
Society for Hospital Pharmacy (SEHF). GENESIS shared 
assessments are made according to a protocol and an agreed 
methodology (MADRE) that takes into account effective-
ness and cost-effectiveness evidence. GENESIS reports are 
a reference for the majority of hospitals in Spain.
The Andalusian and Catalan regions have shown greater 
commitment in the harmonisation of processes for the 
evaluation of new medicines. In 2002, the Andalusian HTA 
agency (AETSA) published a guide to the introduction of 
new medicines (GINF guidance) to facilitate the decisions 
on the inclusion of new medicines on hospital formularies 
[14]. In 2008, the Andalusian Health Service (SAS), estab-
lished an advisory commission to harmonise the utilisation 
criteria for hospital medicines. The recommendations by the 
Andalusian Hospital Formulary guidance (GFTHA reports) 
are implemented by the SAS and hospitals within the region 
tend to endorse its guidance. GENESIS and GFTHA activi-
ties are coordinated to avoid duplication of assessments; and 
both use the GINF classification system to advise on the 
inclusion (categories C2, D, E) or non-inclusion (categories 
A, B, C1) of the medicine for hospital use.
Similarly, in 2008, the Catalan Health Service (Catsalut) 
established a harmonisation programme for pharmaceuticals 
(PHF) to guarantee equity in access to medicines and to 
improve efficiency in daily practice [15]. The PHF has a spe-
cific stream related to hospital medicines dispensed in out-
patient care (PHF-MHDA), which operates with a technical 
committee (CAMHDA) and an executive committee (CFT-
MHDA). PHF-MHDA follows a deliberative process based 
on CAMHDA assessment reports, which are conducted 
using GENESIS methodology, and relies on the consensus 
of both committees. Finally, the CFT-MHDA agrees on the 
level of restriction that applies to each medicine, which can 
be approved for a specific subgroup of patients, approved on 
individual patient basis or on a compassionate use regimen. 
Hence, PHF-MHDA final recommendations are manda-
tory in Catalonia and apply to every hospital in the region. 
While CatSalut is responsible for funding, the Spanish MSC) 
retains the competency of pricing and reimbursement (P&R) 
of medicines and, therefore, anchors regional policies to 
P&R agreements.
Lozano-Blázquez et al. (2015) compared the assessment 
processes for cancer medicines in England and Spain over 
the period January 2011–December 2013 [16]. They found 
that Spain produced more reports over that period compared 
to England (which is expected, as NICE only reviews a selec-
tion of technologies, prioritised according to some defined 
criteria); and also that NICE rejected a higher proportion 
of medicines. Lozano-Blázquez et al. (2015) provide some 
rationale for these differences; for example, more organisa-
tions conducting assessments in Spain are using more simple 
processes. The authors also point out that multiple regional 
or local reassessments may produce delays in access to can-
cer medicines [17].
The objective of this research was to study the impact 
of economic evaluation on the utilisation of cancer medi-
cines in England and Spain. Although, the research can-
not determine whether a centralised or regional approach to 
HTA is superior, by studying two countries with different 
approaches, we hoped to provide evidence that would be 
relevant to a wide range of European countries. Our aim was 
to extend the analysis of Lozano-Blázquez et al. (2015) in 
three ways: (i) by studying a longer time period, we expected 
our sample to include more medicines for which assessments 
had been made in both countries; (ii) by studying in more 
detail the assessment methods used, we hoped to shed more 
light on the relative consistency and rigour of the assess-
ments in the two countries; and, more importantly, (iii) by 
analysing data on the utilisation of medicines over time, we 
hoped to explore what impact, if any, the assessments had 
on the access to, and use of, cancer medicines in the two 
countries.
Methods
Analysis of technology assessments
Data from both countries were extracted for all cancer medi-
cines assessed during the period January 2008 to July 2015. 
We compared NICE reports with Spanish reports avail-
able at national level (e.g. IPT reports); regional level (e.g. 
GENESIS shared reports, CAMHDA reports and GFTHA 
reports); and hospital level (e.g. GENESIS reports from 
individual hospitals). Details were obtained of the medicines 
and indications studied, the methods used, the assessment 
(of clinical or cost-effectiveness) made and the resulting rec-
ommendations. NICE decisions were classified as recom-
mended, restricted and not recommended in accordance with 
a previous analysis [18]. In addition, we recorded whether 
the recommendation was accompanied by a PAS.
For the GFTHA and GENESIS reports, we followed a 
similar rational to Lozano et al. and used the categories 
within the GINF classification to classify decisions as rec-
ommended (C2 and E); restricted (D) and not recommended 
(A, B, C1). CAMDHA decisions were classified as restricted 
(e.g. if approved for a specific subgroup or approved on an 
individual patient basis) and not recommended (e.g. compas-
sionate use only). Positioning statements from IPT reports, 
and those GENESIS reports where the GINF system was not 
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explicitly followed, were analysed by an oncologist author 
(JMB) who advised on the most suitable classification.
The recommendations made by NICE and the Spanish 
bodies were compared in a descriptive analysis. Similarly, 
within Spain, comparisons were made between different 
evaluation bodies in cases where more than one assessment 
existed.
Analysis of data on medicine utilisation
We extracted monthly MIDAS (Medical Information Data 
Analysis System) data (made available by IQVIA) for the 
period from January 2011 to December 2016 measured in 
counting units (i.e. utilisation) and sales (i.e. expenditure in 
US dollars) for both countries. In addition, we extracted uti-
lisation data for Catalonia (made available by CatSalut [Ger-
ència de Farmàcia i del Medicament]), to assess whether 
regional usage was more responsive than national usage to 
recommendations made at the regional level.
Medicines were selected for this part of the analysis based 
on the following criteria (i) the medicine was for a single 
indication, or one major indication responsible for most of 
the usage; (ii) it had been assessed in that indication in both 
countries; and (iii) data were available for the full period of 
the analysis. Applying these criteria resulted in a sample 
of 11 medicines, representing the whole range of possible 
recommendations (e.g. recommended in both countries, not 
recommended in both countries, mixed recommendations 
across the two countries).
Volume results were presented in milligrams, in accord-
ance with other existing analyses comparing the use of can-
cer medicines [19–21]. To determine the total utilisation 
in milligrams, the counting units were multiplied by the 
strength of the product (e.g. mg in a tablet, or mg per ml) 
in each case. To make calculations between both countries 
comparable, total utilisation in milligrams was estimated per 
100,000 population. Population figures were obtained from 
The Office for National Statistics, the Instituto Nacional de 
Estadistica and the Instituto Estadistica Catalonia. In addi-
tion, since it is possible that the relative incidence of some 
cancers varies across populations, volumes (per 100,000 
people) were adjusted by cancer incidence rates. Country-
specific cancer incidence estimates were obtained from 
GLOBOCAN (data available for 2012). Throughout the 
paper, we use the incidence-adjusted analysis when discuss-
ing the impact of cancer recommendations made by NICE 
and Spanish HTA bodies on medicine utilisation in both 
settings.
The trend of medicines utilisation was then analysed to 
assess whether the reports published in either country had 
any noticeable impact. We used both descriptive statistics 
and a regression analysis to explore the impact of recom-
mendations on medicine utilisation in England, Spain and 
Catalonia. In the latter, we analysed the 11 cancer medicines 
during 48 trimesters from 2011 to 2016 using a Poisson 
model with an exposure term; which allows us to explore 
the utilisation of a medicine depending on recommendation 
and expenditure, conditional on the incidence of the type of 
cancer the medicine is used for.
Quarterly country medicines expenditure per unit on 
each medicine was used as an explanatory factor of medi-
cine utilisation, as a proxy of the cost of the medicine. Since 
expenditure might be endogenous (i.e. higher expenditure 
is also driven by higher utilisation), we tested the impact of 
excluding this from our model. In addition, we ran a second-
ary analysis to test the impact of considering the anticipated 
treatment cost (e.g. first year acquisition cost of the drug), 
as opposed to expenditure, in the results. Given the variabil-
ity within the Spanish setting, this sensitivity analysis was 
restricted to the English model. The first year acquisition 
cost was estimated since this is the cost figure that would be 
foremost in the mind of local decision-makers deciding on 
how enthusiastically to adopt NICE guidance.
We recognise that there may be other costs (e.g. in admin-
istration of the drug, in treatment of adverse effects), as well 
as cost-offsets (e.g. discontinuation of an existing drug, if 
this is replaced by the new medication, or reductions in other 
non-pharmaceutical costs). However, most of these costs are 
likely to be relatively minor in practice. Where a first year 
treatment cost was cited by NICE, this was the figure used. 
When a cost was not cited, we have estimated treatment cost 
from information on the cost per dose and the number of 
doses given in the first year. In making these calculations, 
we assumed that patients would receive the prescribed dose 
until the end of their chemotherapy treatment regimen, or 
until the time they progress. Inevitably, these estimates are 
approximations, as (i) patients may have less than the pre-
scribed dose due to lack of tolerance or adverse events, (ii) 
some drugs are administered based on the patient’s weight, 
(iii) there could be drug wastage, and (iv) doctors could 
continue treatment even when they progress, especially if 
there are no other therapies available. The costs excluded 
the confidential discounts through PAS schemes, as these go 
to the Department of Health, not the local decision-makers.
The data on recommendations used in the regression 
model were collected from NICE for England and from 
GENESIS reports for Spain; for those medicines where 
multiple GENESIS reports were available, we used the 
date of the first GENESIS report published as the ref-
erence for the analysis. For the purposes of this part of 
the analysis, recommendations were computed as either 
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positive (‘recommended, restricted’) or negative (‘not rec-
ommended’). In Catalonia, medicines recommended for 
compassionate use were recorded as negative recommenda-
tions in the model.
We estimated a Poisson model with an exposure term1 
that allowed us to take into account not just the count nature 
of the utilisation variable but also the different exposure each 
country had to the different types of cancers for which the 
medicines had an indication. The longitudinal models were 
estimated separately for England, Spain and Catalonia, tak-
ing the following form:
where udt, rdt, edt, and mdt are, respectively, the medicine 
utilisation, the recommendation, the expenditure per medi-
cine unit, and inclusion in the Cancer Medicine Fund (for 
England) of medicine d at time t. While ld is a dummy vari-
able for the use of medicine d in combination with another 
medicine. ft is the time fixed effect. We use as an exposure 
term the incidence of the cancer for which the medicine has 
an indication.
Ideally, the model would capture two states of the world: 
the period before the recommendation, and the period after the 
recommendation, which can be either positive or negative. In 
order to understand the impact of the recommendation on the 
utilisation of the medicine, our first model used the positive 
recommendation as the basis for the analysis. Additionally, we 
conducted a second model using negative recommendation 
as the baseline. However, the negative model was difficult to 
compute due to the lack of utilisation data during the period 
before the negative recommendation. Consequently, we were 
unable to discriminate between no recommendation and nega-
tive recommendation for that period, which made results of 
the negative model difficult to interpret. In England, health 
authorities will approve the use of the medicine conditional on 
NICE recommendation. The situation is similar in Catalonia, 
where hospitals are not allowed to use the medicine before 
the PHF-MHDA issues its recommendation; whilst in Spain, 
if there is no recommendation, the medicine is still available 
through the central procedure.
Therefore, given the limitations of the data for the period 
before negative recommendation, we define recommenda-
tion as a positive recommendation, from NICE, GENESIS or 
PHF-MHDA, to understand the impact of that recommenda-
tion on the utilisation of a medicine.
The model coefficients are the proportionate change in 
the utilisation mean from one unit increase. We also present 
the marginal effect of a positive recommendation which is 
휕Eudt∕rdt
= 훽rEudt.
Eudt = Iexp
(
훽rrdt + 훽eedt + 훽lld + 훽mmdt + ft + 휀dt
)
,
Results
Recommendations in technology assessment 
reports
In the period studied, there were 66 appraisals of cancer 
medicines published by NICE in England. A total of 11 
(17%) medicines were recommended, 5 with a PAS. NICE 
restricted 39 (59%) medicines; 21 of which were accom-
panied by a PAS. Finally, 16 (24%) of medicines received 
a negative recommendation by NICE.
In Spain, there were 96 assessments undertaken by a 
range of bodies. We found a total of 17 IPT reports (41% 
Recommended; 53% Restricted; 6% Not Recommended); 
and 79 GENESIS reports (13% Recommended; 65% 
Restricted; 22% Not Recommended).
A total of 53 medicine–indication pairings were 
assessed in both jurisdictions. For these medicines, the 
rate of negative recommendations at the central level in 
England was higher than in Spain, where the MSC tended 
to equally recommend or restrict the use of the medicines. 
The pattern of negative recommendations of NICE and the 
SAS in Andalusia is very similar (43% vs 46%); whereas 
in Catalonia, most of the medicines (85%) were restricted 
based on clinical criteria.
Methods employed in the assessment reports
The methods employed in all the NICE reports closely 
followed the Institute’s methods guidelines and consisted 
of a clinical assessment and a full cost-effectiveness study. 
In addition, where relevant, NICE’s ‘end of life’ guidance 
was employed, whereby the QALYs gained at end of life 
could be valued higher than ‘standard’ QALYs.
The methods employed in the Spanish reports were 
more varied, and were more focused on clinical efficacy 
and budget impact analysis. We found a significant level 
of duplication in the reports published within different 
regions for the same medicine. It is common for reports 
to be based on the same evidence and to cover the same 
time period; hence, the recommendations are similar. 
For example, the CAMDHA and GENESIS reports for 
afatinib were both conducted in 2014, both preceding the 
central IPT report issued for afatinib in 2015. Although 
both organisations recommend the use of the medicine, 
CFT-MHDA is more explicit regarding the clinical crite-
ria that might apply to patients to access the treatment in 
Catalonia. Additionally, it places special focus on patient 
follow-up and the need to record the therapeutic response, 
in a specific registry (registre de pacients i tractaments 
de medicaments hospitalaris de dispensació ambulatòria).
1 We have used a Generalised Linear Models (GLM) framework to 
select the distribution and consequently, the model which has the best 
fit.
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Economic analyses conducted by GENESIS usually con-
sisted of a summary of cost-effectiveness studies published 
by other organisations (e.g. NICE or the Scottish Medicines 
Consortium); incremental cost-efficacy estimates based on a 
non-systematic selection of clinical evidence; and an estima-
tion of the economic impact to the hospital given the number 
of patients eligible for the new treatment. We found that 
the NICE assessment was published before the first Span-
ish report for five medicines out of the eleven medicines on 
which usage data were analysed. The reasons for such time 
differences in publication dates are varied and complex, but 
include the length of the evaluation processes and compa-
nies’ launch strategies, which could favour launching in the 
UK first. Therefore, a number of cost-effectiveness assess-
ments by GENESIS, CAMDHA and GHTHA included 
NICE estimates as source of evidence for the Spanish rec-
ommendation (e.g. afatinib, aflibercept, bendamustine).
We also attempted to explore the impact of the differ-
ent HTA approaches on time to access to cancer treatments. 
However, the complexity and differences between the pric-
ing and reimbursement systems made comparisons difficult, 
even among regions in Spain. When marketing authorization 
is granted by the European Medicines Agency (EMA), the 
MSC initiates a procedure to decide on reimbursement of 
the new product on the national reimbursement list. After 
marketing authorization, the manufacturer first needs to go 
through some administrative tasks with the Spanish Medi-
cines Agency (AEMPS), including obtaining a national 
product code, before the MSC initiates the procedure for 
pricing and reimbursement after the manufacturer appli-
cation. However, different regions follow different publi-
cation procedures and timings; for example, in Catalonia, 
PHF-MHDA is not allowed to issue its recommendations 
until the price of the medicine is set at the central level, 
which might make PHF-MHDA appear slower compared 
with other regional HTA organisations that do not follow the 
same approach. Therefore, in Spain, any delay in access will 
be due to a combination of factors, rather than one specific 
issue, such as the time it takes to carry out the assessment 
itself, or the delay in the company’s application for pricing.
The situation in England is a little clearer, in that the (pos-
itive) recommendations made by NICE have to be imple-
mented by the NHS within 3 months. However, in principle, 
patients can gain access to cancer medicines as soon as they 
are licensed, although in practice most NHS commission-
ers are likely to wait until the NICE report before allowing 
access other than in individual cases.
NICE appeared to be more restricted about the number of 
indications assessed and recommended for each medicine, 
although the CDF was in place to fund uses of medicines 
not recommended initially by NICE. In Spain, despite the 
absence of a specific mechanism to fund those medicines 
that were not recommended, we found that different regions 
did provide funding for different indications across the 
country.
Descriptive analysis of medicines utilisation
Medicine usage over time was assessed to explore the level 
of impact of assessment reports in the two jurisdictions. We 
defined ‘impact’ to be ‘evidence of a change in the rate of 
usage within 3 months of the report being published’. We 
chose a period of 3 months, since it was unrealistic to expect 
reports to have an instant impact. Also, 3 months is the 
period given to the NHS in England to implement the rec-
ommendations made by NICE in its technology appraisals.
The 11 medicines and indications analysed for sales 
trends/usage were: afatinib (non-small-cell lung cancer), 
aflibercept (colorectal cancer), bendamustine (leukaemia), 
crizotinib (non-small-cell lung cancer, dabrafenib (mela-
noma), enzalutamide (prostate cancer), ipilimumab (mela-
noma), ofatumumab (leukaemia), pazopanib (renal cell car-
cinoma), vemurafenib (melanoma) and vinflunine (urothelial 
carcinoma). (Fuller details of the medicines studied, the 
HTA decisions made and the organisations making them 
are given in Appendix 1).
Graphs of medicines sales/usage over the period January 
2011–December 2016 for England and Spain are given in 
Figs. 1, 2, 3. In each case, the dates of assessment reports 
in England (dash vertical line) and Spain (dotted vertical 
line), and P&R date by MSC in Spain (solid vertical line) 
are shown on the graph. For the purposes of the presentation, 
the medicines are discussed in three groups, according to 
the recommendations made in the two countries. Figures 4, 
5 show the medicines sales/usage over the same period for 
Catalonia. These are presented separately as the data are 
from a different dataset.
Detailed interpretation of the trends for the various medi-
cines is given in Appendix 2, but a few general points are 
made here. First, in considering the graphs for England and 
Spain (Figs. 1, 2, 3), it is clear that in both countries, there 
is some utilisation of all the medicines before any recom-
mendation is made by an HTA agency. For most, but not 
all, of the medicines receiving a positive recommendation, 
there was an increase in the rate of utilisation following the 
recommendation, although in many cases there was already 
an upward trend in utilisation before the recommendation.
Secondly, although the HTA recommendations did have 
an impact, it is clear that other factors were influencing uti-
lisation of the medicines concerned. One possible impor-
tant factor was the launch of other medicines for the same 
patient group. This is one possible explanation for the usage 
of ipilimumab, which has the most complex pattern of those 
examined. The usage increased in both countries following 
a positive recommendation, but then fell away dramatically 
around the end of 2015. This could have been because of the 
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launch of nivolumab, a competitor medicine in a new class 
(immunotherapy) around that time.
Thirdly, considering the medicines with negative recom-
mendations in both countries, usage was never eliminated 
and in some cases did not fall. This emphasises the need for 
recommendations to be made in a timely fashion, since it 
is more difficult to control usage once the drug is already 
being prescribed.
Turning to the data from Catalonia (Figs. 4 and 5), the 
most striking finding is that in most cases, there was lim-
ited use of the medicines before the first recommendation. 
As in England and Spain (in general), usage of medicines 
increased following a positive recommendation. In situations 
where there was a negative recommendation, the usage fell 
more than in England and Spain, although in only one case 
(vinflunine) did this fall seem to be clearly attributable to the 
negative recommendation.
Model results
Although the descriptive analysis of the 11 medicines gives 
some insights, it is clear that HTA guidance is not the only 
factor influencing usage, leading to differences in the impact 
of recommendations for individual medicines. However, we 
wanted to obtain an overall assessment of whether, on aver-
age, the guidance had a substantial impact. Therefore, we 
undertook a regression analysis to understand the impact 
of guidance on the overall utilisation of the 11 medicines in 
total in the two countries.
We observed that the utilisation and expenditure for each 
medicine varied across countries and over time. Also, the 
number of observations for each medicine differs across 
countries, since the medicine’s availably or utilisation 
might have begun at different points in time. Similarly, 
the recommendations from NICE, GENESIS and Spanish 
regional HTA organisations were issued at different times. 
For example, the NICE recommendation for bendamustine 
was in place for the full period analysed, since the decision 
Fig. 2  Medicines Not Recommended in both countries (UK and Spain usage)
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was made in February 2011. In Spain, data on bendamustine 
usage were available from the first trimester of 2011; how-
ever, the GENESIS positive recommendation came in the 
third trimester of 2011. Hence, a recommendation for this 
medicine was in place for only 92% of our analysis period. 
Therefore, we chose a Poisson model, since this enables us 
to examine trends in the use of the medicines in relation to 
‘exposure time’ to the guidance in each country.
The Poisson model results (Table 1) reveal that there is an 
increase of utilisation in England, Spain and Catalonia once 
the medicine has been positively recommended by NICE, 
GENESIS or PHF-MHDA, respectively. If there is a recom-
mendation for the cancer medicine to be used in combination 
with another one, the utilisation decreases in England and 
Spain, but shows a small increase in Catalonia. In England, 
the CDF is used as a mechanism to fund the utilisation of 
medicines that are not recommended by NICE. In our model, 
there is a positive and significant coefficient of the CDF 
on the utilisation of those medicines not recommended by 
NICE, but funded by the CDF.
The coefficient for a CAMDHA positive recommendation 
(4.892) is higher than the one for NICE (3.120) and GEN-
ESIS (1.693). Also, inclusion in the CDF increases utilisation 
in England, but not as much as a positive recommendation 
by NICE (0.453). The time trend was included to capture 
the quarterly increase on cancer medicine utilisation in each 
region. In both countries, the units consumed (adjusted by 
1000 population incidence) before a negative recommenda-
tion is quite low (9.2 in Spain versus 30 in England). Before a 
positive recommendation, the utilisation is lower in England 
than in Spain (597 versus 1458). After a positive recommen-
dation, the units consumed (16 639 in England versus 11,310 
in Spain) is more than 100 times bigger than after a negative 
recommendation (101 in England versus 182 in Spain).
The time effects capture the upper time trend of the can-
cer medicines utilisation. The medicine expenditure variable 
is negatively associated with the cancer medicine utilisa-
tion in all the three jurisdictions.2 Results for England are 
Fig. 3  Mixed recommendations across the two countries (UK and Spain usage)
2 Models for England, Spain and Catalonia without the expenditure 
show very similar results (results are available by request to authors).
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robust to sensitivity analysis, showing that, when using the 
anticipated treatment cost as an independent variable, con-
clusions do not change. Therefore, the use of treatment costs 
instead of expenditure unit cost does not change our main 
result, that a positive recommendation by NICE increases 
significantly the utilisation of cancer drugs. (Further details 
on the sensitivity analysis are given in Appendix 3). Our 
initial analysis plan stated that sensitivity analyses on the 
Fig. 5  Medicines Not Recommended in Catalonia (Catalonia usage)
Table 1  Results of Poisson model
T-statistics in parentheses. * p value < 0.05, **p-value < 0.01 and ***p-value < 0.001
We have also included a time trend in all the models to capture the quarterly increase on cancer medicine utilisation
a Additionally, we run a secondary analysis to test the impact of considering the anticipated treatment cost (e.g. first year acquisition cost of the 
drug), as independent variable in the model for England
b The coefficient [(− 0.0108*** (− 238.26)] for the new independent variable [treatment costs (in £1000)] shows same results (e.g. the higher the 
treatment cost, the lower the drug utilisation is)
England Spain Catalonia
Expenditure per unit (in 1000’s of USD)a − 0.414*** (− 587.13)b − 1.035*** (− 501.94) − 1.308*** (− 149.59)
Used in combination with another medicine − 0.336*** (− 225.41) − 0.480*** (− 100.22) 0.0407*** − 4.98
CDF (not recommended medicines) 0.453*** − 83.96
Positive recommendation by NICE 3.120*** (903.05)
Positive recommendation by GENESIS/Spain 1.693*** (277.1)
Positive recommendation by CAMDHA/Spain 4.892*** (139.36)
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Spanish and Catalan settings would be conducted only if the 
sensitivity analysis on the English setting showed an impact 
in the results. Given that no impact was shown for England, 
sensitivity analyses using Spanish and Catalan data were 
not conducted.
The marginal effect of a positive recommendation is of 
31,495,000 units for England, 6,791,000 units for Spain and 
1,855,000 units for Catalonia. The magnitude of the mar-
ginal effect reflects not only the magnitude of the positive 
recommendation coefficient (reported above in Table 1) but 
also the average number of units utilised in each jurisdiction.
Discussion
Our main finding was that positive HTA recommendations 
had an impact in both England and Spain. Within Spain, the 
impact was higher in Catalonia, a region with a strong track 
record of HTA.
The regional approach in Spain generated a higher num-
ber of HTA reports than in England. Although there was 
some duplication of effort in Spain, guidance was issued 
for 96 medicine/indication pairings, as compared with 
66 in England. All the English reports followed NICE’s 
methods guidelines and produced an estimate of the incre-
mental cost per quality-adjusted life-year (QALY) gained. 
However, some reports in Spain only addressed clinical 
effectiveness as opposed to cost-effectiveness, or just 
gave a summary of the results reported in an earlier NICE 
report. In addition, while the decision rule used to arrive 
at recommendations was clear in England, being based on 
the incremental cost per QALY gained, it was not clear in 
the Spanish reports.
Whether this suggests that the quality of reports is lower 
in Spain is a matter of judgement. Our view is that, while 
evidence on clinical effectiveness alone is useful, a decision 
on whether to use a drug should be based on clinical and 
cost-effectiveness. In addition, consistency in reporting is 
important if reliable comparisons of clinical or cost-effec-
tiveness are to be made between different medicines. The 
variation in approach in Spain is understandable, given the 
range of organisations involved and the potential differences 
in their interests, or, in the case of IPT reports, a differ-
ence in the remit. In addition, despite the processes already 
in place to improve coordination between the national and 
regional levels, we observed a significant level of duplica-
tion of effort. It might be worth discussing ways in which 
communication is improved to promote a more efficient and 
systematic use of HTA resources.
The descriptive analysis on 11 medicines illustrated that, 
on some occasions, the recommendations in HTA reports 
appeared to impact on usage, but on other occasions not. Our 
main finding here is that usage is likely to be impacted by a 
number of factors and not just the HTA guidance. The fac-
tors probably include physicians’ own views on the effective-
ness and cost-effectiveness of the various medicines and the 
availability of other medicines for the same patient group. 
For example, when we examined the consumption in both 
countries before a positive recommendation being released, 
we found that there was almost three times more consump-
tion in Spain than in England, which on the one hand shows 
that recommendations have more effect in England, but, on 
the other hand, implies that patients in England were more 
likely to be denied early access to therapies that were eventu-
ally shown to be cost-effective.
It is not clear which situation is ‘better’ than the other. If 
one believes that the utilisation of drugs should be driven 
by the evidence of clinical and cost-effectiveness, the situ-
ation in England is to be preferred. If, on the other hand, 
one believes that patients should have access to promising 
new therapies unless these are shown not to be clinical or 
cost-effective, the situation in Spain is to be preferred. The 
reverse situation is observed for the consumption of medi-
cines before negative recommendations. Although in both 
countries, there is usage of drugs that are eventually shown 
not to be cost-effective, the usage prior to negative recom-
mendations was lower in Spain. One explanation is that, in 
England, the situation was complicated by the existence of 
the CDF, which at the time of our analysis provided fund-
ing for some medicines that had not received positive rec-
ommendations from NICE. However, although our sample 
was small, the impact of negative recommendations in Eng-
land, where they are mandatory for the NHS, appeared to be 
stronger than that in Spain.
The regression analysis showed that, overall, positive 
recommendations had an impact on medicine usage in both 
England and Spain. The interesting finding here was that, 
although the strength of the impact on usage, as judged by 
the size of the coefficient, was higher in England than Spain, 
the strength of impact in Catalonia was the highest of all. 
As shown in the graphs, one possible explanation is that the 
lower effect of positive recommendation in Spain is driven 
by the fact that there is more utilisation before the recom-
mendation; whereas in Catalonia, there is almost none. A 
positive recommendation still increases medicines’ usage 
in Spain, but probably increases it less because there was 
often substantial utilisation before the recommendation. 
This can be interpreted as an indication that a central sys-
tem would allow for a better control of the medicines that 
are prescribed both before and after the recommendation. 
Whereas, a decentralised system such as in Spain, that was 
shown to be more variable with less clear guidance, showed 
lower control in the utilisation of medicines.
The finding of a strong impact of recommendations in 
Catalonia should be treated with some caution, since the 
data on medicine usage came from a different source, but 
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they do lend some support to our hypothesis that local 
recommendations may have a greater impact. However, if 
true, it has implications for both the central and regional 
approaches to HTA.
For the central approach, the message is that, although 
centrally produced recommendations do have an impact, 
it still may be worthwhile putting effort into methods to 
encourage local adoption of the recommendations. For the 
regional approach, the message is that locally generated 
recommendations can have a strong impact, but that such 
an approach needs to be uniformly applied. For example, 
although there are 17 regions in Spain, only a minority 
of regions follow a structured HTA approach, with some 
regions having no locally produced reports at all. It appeared 
that in such a decentralised system, a substantial amount of 
decision-making is taking place at local level, especially in 
those hospitals where pharmacy committees work closely 
with HTA bodies to sustain a rational use and funding of 
medicines. This may be one factor contributing to the lower 
impact of guidance overall in Spain.
The evidence presented here relates to England and 
Spain. Inevitably, different features will apply in other 
countries, which limits the generalisability of our results. 
However, given similarities in HTA policies and processes in 
many other centralised and decentralised countries, we sug-
gest that our conclusions may well be transferable. However, 
most importantly, our general findings suggest that invest-
ments in HTA, either centrally or regionally, can influence 
the usage of cancer medicines.
Conclusions
The decision on whether HTA capacity is organised cen-
trally or regionally depends on a number of factors, not least 
the level of autonomy granted to regions in the country’s 
constitution. This study shows that HTA recommenda-
tions made either centrally or regionally can impact upon 
medicine usage. However, if capacity is organised region-
ally, considerable effort may be required in coordination, to 
ensure consistent and rigorous assessments and adequate 
implementation of HTA findings.
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